GSA Capital Partners’s ADC Therapeutics ADCT Stock Holding History

GSA Capital Partners’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59K	Buy	+54,695	New	+$160K	﹤0.01%	1652
2026 Q1	–	Sell	-20,889	Closed	-$74K	–	1671
2025 Q4	$74K	Buy	+20,889	New	+$84.8K	0.01%	1555
2023 Q4	–	Sell	-121,897	Closed	-$109K	–	1447
2023 Q3	$109K	Buy	121,897 +13,012	+12%	+$17.3K	0.01%	1377
2023 Q2	$234K	Buy	108,885 +85,237	+360%	+$192K	0.02%	1181
2023 Q1	$46K	Buy	+23,648	New	+$87.2K	﹤0.01%	1404

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GSA Capital Partners's ADCT Position: Q2 2026 in Review

GSA Capital Partners opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 54,695 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #1652 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in ADCT as recently as Q4 2025.

GSA Capital Partners first reported a position in ADCT in Q1 2023 and has held it in 5 quarters since. The position peaked at $234K in Q2 2023. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

GSA Capital Partners held 54,695 shares of ADC Therapeutics worth $59K as of Q2 2026.
ADC Therapeutics was a new GSA Capital Partners position in Q2 2026.
ADC Therapeutics made up ﹤0.01% of GSA Capital Partners's portfolio in Q2 2026, its #1652 holding.
GSA Capital Partners first reported a position in ADC Therapeutics in Q1 2023 and has held it in 5 quarters since.
GSA Capital Partners's ADC Therapeutics position peaked at $234K in Q2 2023.
113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.